The classification and monitoring of individuals with early knee osteoarthritis (OA) are
important considerations for the design and evaluation of therapeutic interventions and …

Baricitinib, an oral selective Janus kinase (JAK) 1/JAK2 inhibitor, is approved as
monotherapy or in combination with methotrexate for treating adults with moderate-to-severe …

Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in
patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) …

Objectives Combining disease-modifying antirheumatic drugs (DMARDs) with
glucocorticoids (GCs) is an effective treatment strategy for early rheumatoid arthritis (ERA) …

Background With respect to patient-centered care, measuring care effects based on patient-
relevant outcomes is becoming increasingly important. There is some uncertainty about …

Objectives To investigate whether MTX should be combined with an additional DMARD and
bridging glucocorticoids as initial treatment for patients with early RA to induce an effective …

Objective This study investigated how psychosocial aspects of disease affect the probability
of achieving sustained remission in early rheumatoid arthritis (RA) and explored the …

Objectives This post hoc analysis assessed speed, magnitude and maintenance of pain
improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib …

Background Rheumatoid arthritis (RA) considerably impacts patients' mental health.
However, it is largely unclear how people suffering from RA experience psychological stress …

Objective Fatigue is common in rheumatoid arthritis (RA). We aimed to explore its
longitudinal course, predictors and association with disease activity in early RA. Methods …